Literature DB >> 3755993

Multiple primary malignancies in head and neck cancer.

A H Shikhani, G M Matanoski, M M Jones, H K Kashima, M E Johns.   

Abstract

Multiple primary (MP) malignancies were found in 9.7% of 1961 patients with primary head and neck cancer diagnosed at The Johns Hopkins Hospital, Baltimore, during the years 1975 to 1985. The index tumors were divided into six main groups. Out of the 190 MP malignancies, 46.9% were synchronous and 53.1% were metachronous. Seventy-four percent of MP lesions were noted during the first year after diagnosis of the index primary tumor. Patients with an index tumor in the upper aerodigestive tract had a significantly increased risk of developing a second cancer in the head and neck area. This risk was 5.94 for the oral cavity, 6.98 for the pharynx, 3.57 for the larynx, and 7.02 for the esophagus. Patients with an index tumor in the salivary gland or the thyroid gland had, respectively, a 3.59 and a 7.38 higher risk than the general population of developing a second tumor. Efforts aimed at improving the survival of patients with head and neck cancer must incorporate strategies for the prevention, early detection, and treatment of MP neoplasms.

Entities:  

Mesh:

Year:  1986        PMID: 3755993     DOI: 10.1001/archotol.1986.03780110048006

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  9 in total

1.  Synchronous papillary urothelial carcinoma of the bladder and squamous cell carcinoma with sarcomatoid differentiation: A case report.

Authors:  Mahizer Yaldiz; Nur Cihan Cosansu; Berna Solak; Zeynep Kahyaoglu; Mustafa Teoman Erdem
Journal:  Oncol Lett       Date:  2016-08-30       Impact factor: 2.967

Review 2.  Multiple primary tumours of the urogenital system: our cases and a review of the literature.

Authors:  A S Ozdamar; E Y Gültekin; A Gökalp
Journal:  Int Urol Nephrol       Date:  1997       Impact factor: 2.370

3.  Second primary esophageal or lung cancer in patients with head and neck carcinoma in Taiwan: incidence and risk in relation to primary index tumor site.

Authors:  Min-Chi Chen; Ping-Tsung Chen; Chunghuang Hubert Chan; Cheng-Ta Yang; Chih-Cheng Chen; Cih-En Huang; Chang-Hsien Lu; Kuan-Der Lee
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-20       Impact factor: 4.553

4.  Second primary tumours in oropharyngeal squamous cell carcinoma.

Authors:  Franz-Josef Kramer; Marcel Janssen; Andre Eckardt
Journal:  Clin Oral Investig       Date:  2004-03-16       Impact factor: 3.573

5.  Early detection in head and neck cancer - current state and future perspectives.

Authors:  Andreas O H Gerstner
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2010-10-07

6.  Incidence and Outcomes of Patients With Oral Cavity Squamous Cell Carcinoma and Fourth Primary Tumors: A Long-term Follow-up Study in a Betel Quid Chewing Endemic Area.

Authors:  Mohamad Adel; Chun-Ta Liao; Li-Yu Lee; Chuen Hsueh; Chien-Yu Lin; Kang-Hsing Fan; Hung-Ming Wang; Shu-Hang Ng; Chih-Hung Lin; Chung-Kan Tsao; Shiang-Fu Huang; Chung-Jan Kang; Ku-Hao Fang; Yu-Chien Wang; Kai-Ping Chang; Tuan-Jen Fang; Lan Yan Yang; Tzu-Chen Yen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Risk of new primary cancer in patients with oropharyngeal cancer.

Authors:  A L Söderholm; E Pukkala; C Lindqvist; L Teppo
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

8.  p53 oncoprotein overexpression correlates with mutagen-induced chromosome fragility in head and neck cancer patients with multiple malignancies.

Authors:  O Gallo; S Bianchi; M L Giovannucci-Uzzielli; R Santoro; S Lenzi; C Salimbeni; M Abbruzzese; E Alajmo
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

9.  Second primary malignancies in thyroid cancer patients.

Authors:  C Rubino; F de Vathaire; M E Dottorini; P Hall; C Schvartz; J E Couette; M G Dondon; M T Abbas; C Langlois; M Schlumberger
Journal:  Br J Cancer       Date:  2003-11-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.